title: Targeted knockdown of Bcl2 in tumor cells using a synthetic TRAIL 3'-UTR microRNA.
abstract: Targeting tumor-related overexpression of anti-apoptotic Bcl2 protein by RNAi has been suggested as a potential treatment for cancer. However, the stability of RNAi and its delivery are still major obstacles to the clinical testing of Bcl2 RNAi. Here, we explore a novel strategy of expressing a synthetic Bcl2 microRNA (smRNA) in the 3' untranslated region (UTR) of the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), an apoptosis-inducing protein without apparent toxic effects in normal cells. TRAIL was specifically expressed from the human telomerase reverse transcriptase promoter (pTRT) that is active in many human tumors. Using this approach, we demonstrated that pTRT drove the tumor-specific expression of Bcl2 smRNA, which was processed by the host RNAi machinery and silenced endogenous Bcl2 expression in tumor cells. Bcl2 smRNA induced tumor cell apoptosis by activating caspase-3 and led to significant sensitization of tumor cells to TRAIL-induced apoptosis, while normal cells were spared. We also showed that the combined therapy of TRAIL-induced apoptosis and Bcl2 downregulation was superior to the mono-therapy of TRAIL or Bcl2 smRNA alone. This study proves a general paradigm for cancer therapy by using 3' UTR microRNA technology.
authors.affiliation: Department of Biochemistry and Molecular Biology, Shanghai Jiao Tong University School of Medicine, Shanghai, People's Republic of China.
authors.forename: Jianjun
authors.initials: J
authors.lastname: Zhang
authors.forename: Shenglin
authors.initials: S
authors.lastname: Huang
authors.forename: He
authors.initials: H
authors.lastname: Zhang
authors.forename: Haibo
authors.initials: H
authors.lastname: Wang
authors.forename: Haiyan
authors.initials: H
authors.lastname: Guo
authors.forename: Guanxiang
authors.initials: G
authors.lastname: Qian
authors.forename: Xianqun
authors.initials: X
authors.lastname: Fan
authors.forename: Jian
authors.initials: J
authors.lastname: Lu
authors.forename: Andrew R
authors.initials: AR
authors.lastname: Hoffman
authors.forename: Ji-Fan
authors.initials: JF
authors.lastname: Hu
authors.forename: Shengfang
authors.initials: S
authors.lastname: Ge
mesh_terms: D020413:3' Untranslated Regions / Q000235:genetics*; D017209:Apoptosis; D045744:Cell Line, Tumor; D006801:Humans; D035683:MicroRNAs / Q000627:therapeutic use*; D009369:Neoplasms / Q000628:therapy*; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000037:antagonists & inhibitors* / Q000235:genetics; D034622:RNA Interference; D053221:TNF-Related Apoptosis-Inducing Ligand / Q000235:genetics*
chemical_list: D020413:3' Untranslated Regions; D035683:MicroRNAs; D019253:Proto-Oncogene Proteins c-bcl-2; D053221:TNF-Related Apoptosis-Inducing Ligand; C505653:TNFSF10 protein, human
references.citation: Cell. 2002 Jan 25;108(2):153-64
references.pmid: 11832206
references.citation: Cell Death Differ. 2004 Aug;11(8):915-23
references.pmid: 15118763
references.citation: Mol Ther. 2009 Jan;17(1):57-64
references.pmid: 19018252
references.citation: Cancer Cell. 2002 Sep;2(3):243-7
references.pmid: 12242156
references.citation: Clin Cancer Res. 2004 Nov 15;10(22):7721-6
references.pmid: 15570006
references.citation: Cancer Res. 1994 Jun 15;54(12):3253-9
references.pmid: 8205548
references.citation: Med Hypotheses. 2007;69(3):537-40
references.pmid: 17363184
references.citation: Nat Rev Cancer. 2002 Sep;2(9):647-56
references.pmid: 12209154
references.citation: Invest New Drugs. 2008 Apr;26(2):193-4
references.pmid: 18060598
references.citation: Semin Hematol. 1997 Oct;34(4 Suppl 5):9-19
references.pmid: 9408956
references.citation: Cancer Gene Ther. 2004 May;11(5):309-16
references.pmid: 15031723
references.citation: Nat Rev Drug Discov. 2002 Feb;1(2):111-21
references.pmid: 12120092
references.citation: Science. 1998 Aug 28;281(5381):1322-6
references.pmid: 9735050
references.citation: Proc Natl Acad Sci U S A. 2005 Mar 8;102(10):3627-32
references.pmid: 15738415
references.citation: Life Sci. 2008 Jun 6;82(23-24):1154-61
references.pmid: 18485417
references.citation: Genes Dev. 2003 Apr 15;17(8):991-1008
references.pmid: 12672692
references.citation: Hematol Oncol. 2002 Jun;20(2):63-74
references.pmid: 12111869
references.citation: Curr Biol. 2002 Apr 30;12(9):735-9
references.pmid: 12007417
references.citation: Crit Rev Oncol Hematol. 2002 Jan;41(1):57-77
references.pmid: 11796232
references.citation: Cell Mol Neurobiol. 2006 Jul-Aug;26(4-6):425-38
references.pmid: 16710755
references.citation: Int J Cancer. 2004 Jan 1;108(1):71-7
references.pmid: 14618618
references.citation: Oncology (Williston Park). 2003 Sep;17(9):1244-6, 1251-3, 1258
references.pmid: 14569852
references.citation: J Biol Chem. 1996 Jul 26;271(30):18253-62
references.pmid: 8663390
references.citation: Am J Dermatopathol. 1995 Feb;17(1):7-11
references.pmid: 7695015
references.citation: Br J Cancer. 2004 Jul 5;91(1):171-7
references.pmid: 15173860
references.citation: Science. 2004 Apr 23;304(5670):594-6
references.pmid: 15105502
references.citation: Cell. 1994 Aug 26;78(4):539-42
references.pmid: 8069905
references.citation: Blood. 1993 Jun 1;81(11):3091-6
references.pmid: 7684624
references.citation: J Clin Invest. 1999 Jul;104(2):155-62
references.pmid: 10411544
references.citation: Genome Res. 2004 Oct;14(10A):1902-10
references.pmid: 15364901
references.citation: Hum Immunol. 2005 Mar;66(3):274-84
references.pmid: 15784465
references.citation: Biochim Biophys Acta. 2004 Mar 1;1644(2-3):229-49
references.pmid: 14996506
references.citation: EMBO J. 2006 Nov 15;25(22):5329-38
references.pmid: 17082775
references.citation: Clin Cancer Res. 2004 Jun 1;10(11):3667-77
references.pmid: 15173073
references.citation: J Biol Chem. 1997 Aug 15;272(33):20715-20
references.pmid: 9252392
references.citation: Nat Rev Drug Discov. 2008 Dec;7(12):1001-12
references.pmid: 18989337
references.citation: Nat Rev Cancer. 2005 Nov;5(11):876-85
references.pmid: 16239906
references.citation: Apoptosis. 2001 Jun;6(3):191-7
references.pmid: 11388668
references.citation: Cancer Gene Ther. 2002 Feb;9(2):164-72
references.pmid: 11857034
references.citation: Cancer Gene Ther. 2003 Jul;10(7):540-8
references.pmid: 12833134
references.citation: Curr Opin Investig Drugs. 2001 Apr;2(4):574-80
references.pmid: 11566020
references.citation: Proc Natl Acad Sci U S A. 2002 Nov 12;99(23):14849-54
references.pmid: 12403821
references.citation: J Clin Oncol. 2008 Feb 20;26(6):870-6
references.pmid: 18281659
references.citation: Biochim Biophys Acta. 1999 Dec 10;1489(1):97-106
references.pmid: 10807000
references.citation: Cell. 2000 Jan 7;100(1):57-70
references.pmid: 10647931
references.citation: Cancer Res. 1992 Dec 15;52(24):6940-4
references.pmid: 1458483
references.citation: Mol Cell. 2004 Dec 22;16(6):861-5
references.pmid: 15610730
references.citation: Acta Pharmacol Sin. 2006 Feb;27(2):242-8
references.pmid: 16412276
references.citation: Immunity. 1995 Dec;3(6):673-82
references.pmid: 8777713
references.citation: Oligonucleotides. 2003;13(5):393-400
references.pmid: 15000830
references.citation: Nucleic Acids Res. 2006 Apr 13;34(7):e53
references.pmid: 16614444